Johan W Mouton

List of Publications by Year in Descending Order

274 papers	12,647 citations	58 h-index	101 g-index
280 ext. papers	14,908 ext. citations	6.6 avg, IF	6.37 L-index

#	Paper	IF	Citations
274	European Society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli (endorsed by ESICM -European Society of intensive care Medicine).. *Clinical Microbiology and Infection*, **2021**,	9.5	27
273	Evaluation of the post-antibiotic effect for the combination of a β-lactam antibiotic and a β-lactamase inhibitor: ceftazidime-avibactam in neutropenic mouse thigh and lung infections. *Journal of Chemotherapy*, **2021**, 33, 400-408	2.3	0
272	Activity of Cefepime in Combination with the Novel β-Lactamase Inhibitor Taniborbactam (VNRX-5133) against Extended-Spectrum-β-Lactamase-Producing Isolates in Checkerboard Assays. *Antimicrobial Agents and Chemotherapy*, **2021**, 65,	5.9	3
271	The Role of New Posaconazole Formulations in the Treatment of Candida albicans Infections: Data from an Pharmacokinetic-Pharmacodynamic Model. *Antimicrobial Agents and Chemotherapy*, **2021**, 65,	5.9	4
270	Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity. *BMC Infectious Diseases*, **2021**, 21, 309	4	1
269	The synthetic synergistic cinnamon oil CIN-102 is active against Madurella mycetomatis, the most common causative agent of mycetoma. *PLoS Neglected Tropical Diseases*, **2021**, 15, e0009488	4.8	1
268	Multicentre testing of the EUCAST broth microdilution reference method for MIC determination on Mycobacterium tuberculosis. *Clinical Microbiology and Infection*, **2021**, 27, 288.e1-288.e4	9.5	3
267	The Effect of Antibiotic Restriction Programs on Prevalence of Antimicrobial Resistance: A Systematic Review and Meta-Analysis. *Open Forum Infectious Diseases*, **2021**, 8, ofab070	1	3
266	In-vitro pharmacokinetic/pharmacodynamic model data suggest a potential role of new formulations of posaconazole against Candida krusei but not Candida glabrata infections. *International Journal of Antimicrobial Agents*, **2021**, 57, 106291	14.3	2
265	Pharmacokinetic/pharmacodynamic analysis of oral fosfomycin against Enterobacterales, Pseudomonas aeruginosa and Enterococcus spp. in an in vitro bladder infection model: impact on clinical breakpoints. *Journal of Antimicrobial Chemotherapy*, **2021**, 76, 3201-3211	5.1	2
264	Exploring the Interplay of Resistance Nodulation Division Efflux Pumps, C and D in Antimicrobial Resistance of Complex in Clinical Isolates. *Microbial Drug Resistance*, **2020**, 26, 1144-1152	2.9	3
263	Efficacy of single and multiple oral doses of fosfomycin against Pseudomonas aeruginosa urinary tract infections in a dynamic in vitro bladder infection model. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 1879-1888	5.1	7
262	Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for Candida albicans Using a Validated Pharmacokinetic/Pharmacodynamic Model. *Antimicrobial Agents and Chemotherapy*, **2020** , 64,	5.9	2
261	Trends, seasonality and the association between outpatient antibiotic use and antimicrobial resistance among urinary bacteria in the Netherlands. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 2314-2325	5.1	5
260	Single-dose pharmacokinetics of temocillin in plasma and soft tissues of healthy volunteers after intravenous and subcutaneous administration: a randomized crossover microdialysis trial. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 2650-2656	5.1	3
259	Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic Model. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	9
258	Guide-free Cas9 from pathogenic bacteria causes severe damage to DNA. *Science Advances*, **2020**, 6, eaaz4849	14.3	16

257	Study protocol for an international, multicentre stepped-wedge cluster randomised trial to evaluate the impact of a digital antimicrobial stewardship smartphone application. *BMJ Open*, **2020**, 10, e033640	3	3
256	Methodological features of clinical pharmacokinetic-pharmacodynamic studies of antibacterials and antifungals: a systematic review. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 1374-1389	5.1	14
255	Evaluation of pooled human urine and synthetic alternatives in a dynamic bladder infection in vitro model simulating oral fosfomycin therapy. *Journal of Microbiological Methods*, **2020**, 171, 105861	2.8	3
254	Population Pharmacokinetics of Imipenem in Critically Ill Patients: A Parametric and Nonparametric Model Converge on CKD-EPI Estimated Glomerular Filtration Rate as an Impactful Covariate. *Clinical Pharmacokinetics*, **2020**, 59, 885-898	6.2	6
253	Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes. *Clinical Microbiology and Infection*, **2020**, 26, 1185-1191	9.5	18
252	A multicentre study to optimize echinocandin susceptibility testing of Aspergillus species with the EUCAST methodology and a broth microdilution colorimetric method. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 1799-1806	5.1	6
251	Voriconazole efficacy against Candida glabrata and Candida krusei: preclinical data using a validated in vitro pharmacokinetic/pharmacodynamic model. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 140-148	5.1	3
250	Bacterial quantification in tissue homogenates from pharmacodynamic studies using growth curves. *Journal of Medical Microbiology*, **2020**, 69, 676-684	3.2	1
249	Zinc-Impregnated Mesh for Abdominal Wall Repair Reduces Infection in a Rat Model of Peritonitis. *Journal of Surgical Research*, **2020**, 246, 560-567	2.5	1
248	Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals. *British Journal of Clinical Pharmacology*, **2020**, 86, 303-317	3.8	18
247	Impact of bacterial species and baseline resistance on fosfomycin efficacy in urinary tract infections. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 988-996	5.1	10
246	Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against : the Importance of Heteroresistance for Growth Outcome. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	8
245	Diagnostic and medical needs for therapeutic drug monitoring of antibiotics. *European Journal of Clinical Microbiology and Infectious Diseases*, **2020**, 39, 791-797	5.3	28
244	Cefpirome Treatment Results in Limited Selection of Stable Derepressed Mutants in the Intestinal Flora of Rats Treated for an Experimental Pulmonary Infection. *Microbial Drug Resistance*, **2020**, 26, 341-348	3.0	
243	Colistin Resistance Development Following Colistin-Meropenem Combination Therapy Versus Colistin Monotherapy in Patients With Infections Caused by Carbapenem-Resistant Organisms. *Clinical Infectious Diseases*, **2020**, 71, 2599-2607	11.6	5
242	Antimicrobial susceptibility testing of Mycobacterium tuberculosis complex isolates - the EUCAST broth microdilution reference method for MIC determination. *Clinical Microbiology and Infection*, **2020**, 26, 1488-1492	9.5	13
241	International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). *Pharmacotherapy* **2019**, 39, 10-39	5.8	280
240	Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Non-obese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study. *Pharmaceutical Research*, **2019**, 36, 112	4.5	8

239	Development and validation of a fast and sensitive UHPLC-DAD assay for the quantification of nitrofurantoin in plasma and urine. *Journal of Pharmaceutical and Biomedical Analysis*, **2019**, 174, 161-167	3.5	4
238	A Prospective Clinical Study Characterizing the Influence of Morbid Obesity on the Pharmacokinetics of Gentamicin: Towards Individualized Dosing in Obese Patients. *Clinical Pharmacokinetics*, **2019**, 58, 1333-1343	6.2	5
237	Variation of MIC measurements: the contribution of strain and laboratory variability to measurement precision-authorsSresponse. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 1761-1762	5.1	6
236	Optimizing dosing of nitrofurantoin from a PK/PD point of view: What do we need to know?. *Drug Resistance Updates*, **2019**, 43, 1-9	23.2	10
235	The pharmacokinetics of nitrofurantoin in healthy female volunteers: a randomized crossover study. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 1656-1661	5.1	7
234	and Exposure-Effect Relationship of Liposomal Amphotericin B against Aspergillus fumigatus. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	3
233	Urinary antibacterial activity of fosfomycin and nitrofurantoin at registered dosages in healthy volunteers. *International Journal of Antimicrobial Agents*, **2019**, 54, 435-441	14.3	6
232	Development and multicentre validation of an agar-based screening method for echinocandin susceptibility testing of Aspergillus species. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 2247-2254	5.1	4
231	Polymyxin Susceptibility Testing and Breakpoint Setting. *Advances in Experimental Medicine and Biology*, **2019**, 1145, 117-132	3.6	3
230	Invasive Aspergillosis by : Epidemiology, Diagnosis, Antifungal Resistance, and Management. *Journal of Fungi (Basel, Switzerland)*, **2019**, 5,	5.6	70
229	An alternative strategy for combination therapy: Interactions between polymyxin B and non-antibiotics. *International Journal of Antimicrobial Agents*, **2019**, 53, 34-39	14.3	21
228	Triple combination of meropenem, colistin and tigecycline was bactericidal in a dynamic model despite mere additive interactions in chequerboard assays against carbapenemase-producing Klebsiella pneumoniae isolates. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 387-394	5.1	8
227	Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial. *Clinical Infectious Diseases*, **2019**, 69, 769-776	11.6	58
226	Pharmacokinetics and Pharmacodynamics of Murepavadin in Neutropenic Mouse Models. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	13
225	A New Marker of Echinocandin Activity in an Pharmacokinetic/Pharmacodynamic Model Correlates with an Animal Model of Aspergillus fumigatus Infection. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	1
224	Colistin versus colistin plus meropenem for severe infections AuthorsSreply. *Lancet Infectious Diseases, The*, **2018**, 18, 495-496	25.5	
223	Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2018**, 319, 1781-1789	27.4	99
222	Fosfomycin as a potential therapy for the treatment of systemic infections: a population pharmacokinetic model to simulate multiple dosing regimens. *Pharmacology Research and Perspectives*, **2018**, 6, e00378	3.1	7

221	Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. *Lancet Infectious Diseases, The*, **2018**, 18, 391-400	25.5	255
220	Exploring colistin pharmacodynamics against Klebsiella pneumoniae: a need to revise current susceptibility breakpoints. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 953-961	5.1	16
219	MIC-based dose adjustment: facts and fables. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 564-568	5.1	150
218	Highly variable absorption of clavulanic acid during the day: a population pharmacokinetic analysis. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 469-476	5.1	13
217	Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 709-719	5.1	21
216	Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 134-142	5.1	21
215	Review of the pharmacokinetic properties of nitrofurantoin and nitroxoline. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 2916-2926	5.1	43
214	Susceptibility of ESBL Escherichia coli and Klebsiella pneumoniae to fosfomycin in the Netherlands and comparison of several testing methods including Etest, MIC test strip, Vitek2, Phoenix and disc diffusion. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 2380-2387	5.1	25
213	Clinical applications of population pharmacokinetic models of antibiotics: Challenges and perspectives. *Pharmacological Research*, **2018**, 134, 280-288	10.2	55
212	Soup with or without meatballs: Impact of nutritional factors on the MIC, kill-rates and growth-rates. *European Journal of Pharmaceutical Sciences*, **2018**, 125, 23-27	5.1	9
211	The stability of antimycobacterial drugs in media used for drug susceptibility testing. *Diagnostic Microbiology and Infectious Disease*, **2018**, 92, 305-308	2.9	11
210	MIC-based dose adjustment: facts and fables-authorsSresponse. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 2585-2586	5.1	7
209	Variation of MIC measurements: the contribution of strain and laboratory variability to measurement precision. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 2374-2379	5.1	42
208	Antifungal Susceptibility Testing of Candida Isolates with the EUCAST Methodology, a New Method for ECOFF Determination. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	23
207	Shortening the incubation time for antimicrobial susceptibility testing by disk diffusion for Enterobacteriaceae: how short can it be and are the results accurate?. *International Journal of Antimicrobial Agents*, **2017**, 49, 631-637	14.3	21
206	Efficacy of Liposomal Amphotericin B against Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates in Two Different Immunosuppression Models of Invasive Aspergillosis. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	5
205	Successful treatment of azole-resistant invasive aspergillosis in a bottlenose dolphin with high-dose posaconazole. *Medical Mycology Case Reports*, **2017**, 16, 16-19	1.7	13
204	Pharmacodynamics of nitrofurantoin at different pH levels against pathogens involved in urinary tract infections. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 3366-3373	5.1	9

203	Multicentre validation of 4-well azole agar plates as a screening method for detection of clinically relevant azole-resistant Aspergillus fumigatus. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 3325-3333	5.1	32
202	Pharmacodynamics of fosfomycin against ESBL- and/or carbapenemase-producing Enterobacteriaceae. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 3374-3381	5.1	19
201	Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	52
200	A fast and sensitive LC-MS/MS method for the quantification of fosfomycin in human urine and plasma using one sample preparation method and HILIC chromatography. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2017**, 1061-1062, 263-269	3.2	20
199	Pharmacodynamics of Cefepime Combined with Tazobactam against Clinically Relevant Enterobacteriaceae in a Neutropenic Mouse Thigh Model. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	9
198	Shortening the incubation time for the combination disk diffusion extended-spectrum β-lactamase (ESBL) confirmation test: how far can we go?. *International Journal of Antimicrobial Agents*, **2017**, 50, 473-476	14.3	
197	Pharmacodynamics of Voriconazole against Wild-Type and Azole-Resistant Aspergillus flavus Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	14
196	The fate of inhaled antibiotics after deposition in cystic fibrosis: How to get drug to the bug?. *Journal of Cystic Fibrosis*, **2017**, 16, 13-23	4.1	30
195	Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 172-180	5.1	5
194	Patient-specific modelling of regional tobramycin concentration levels in airways of patients with cystic fibrosis: can we dose once daily?. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 3435-3442	5.1	11
193	Assessment of Bactericidal Drug Activity and Treatment Outcome in a Mouse Tuberculosis Model Using a Clinical Beijing Strain. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	7
192	Dose optimization of voriconazole/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 3135-3147	5.1	16
191	Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 6374-6	5.9	36
190	Pharmacodynamics and differential activity of nitrofurantoin against ESBL-positive pathogens involved in urinary tract infections. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 2883-9	5.1	14
189	Non-linear absorption pharmacokinetics of amoxicillin: consequences for dosing regimens and clinical breakpoints. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 2909-17	5.1	37
188	Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 1097-105	5.9	64
187	Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 1013-21	5.9	43
186	Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 368-75	5.9	68

185	Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. *Lancet Infectious Diseases, The*, **2016**, 16, 847-856	25.5	352
184	Bacteroides fragilis in biopsies of patients with major abscesses and diabetic foot infections: direct molecular versus culture-based detection. *Diagnostic Microbiology and Infectious Disease*, **2016**, 85, 263-5	2.9	3
183	Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol. *BMJ Open*, **2016**, 6, e009956	3	34
182	General Concepts of Pharmacodynamics for Anti-infective Agents. *Methods in Pharmacology and Toxicology*, **2016**, 3-27	1.1	4
181	Hydrogen cyanide emission in the lung by Staphylococcus aureus. *European Respiratory Journal*, **2016**, 48, 577-9	13.6	9
180	Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 2895-900	5.9	39
179	Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 3779-85	5.9	19
178	Pharmacodynamics of Ceftolozane Combined with Tazobactam against Enterobacteriaceae in a Neutropenic Mouse Thigh Model. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 7272-7279	5.9	22
177	Time-kill kinetics of slowly growing mycobacteria common in pulmonary disease. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 2838-43	5.1	20
176	Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 2456-64	5.1	127
175	Reviving old antibiotics. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 2177-81	5.1	62
174	Antimicrobial prescription patterns of veterinarians: introduction of a benchmarking approach. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 2423-5	5.1	20
173	Genetic Variation in TLR10, an Inhibitory Toll-Like Receptor, Influences Susceptibility to Complicated Skin and Skin Structure Infections. *Journal of Infectious Diseases*, **2015**, 212, 1491-9	7	19
172	Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 2074-7	5.1	38
171	Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. *Seminars in Respiratory and Critical Care Medicine*, **2015**, 36, 136-53	3.9	93
170	Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 2855-66	5.9	52
169	Posaconazole prophylaxis in experimental azole-resistant invasive pulmonary aspergillosis. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 1487-94	5.9	19
168	A Novel Y319H Substitution in CYP51C Associated with Azole Resistance in Aspergillus flavus. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 6615-9	5.9	45

167	In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 4521-5	5.9	19
166	Aspergillus and aspergilloses in wild and domestic animals: a global health concern with parallels to human disease. *Medical Mycology*, **2015**, 53, 765-97	3.9	111
165	In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assays. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 1138-44	5.9	28
164	Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 891-8	5.1	50
163	Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model--authorsSresponse. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 634-5	5.1	4
162	Pharmacodynamics of imipenem in combination with β-lactamase inhibitor MK7655 in a murine thigh model. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 790-5	5.9	32
161	Time-kill kinetics of antibiotics active against rapidly growing mycobacteria. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 811-7	5.1	49
160	Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model. *Antimicrobial Agents and Chemotherapy*, **2015**, 60, 1242-8	5.9	30
159	The strength of synergistic interaction between posaconazole and caspofungin depends on the underlying azole resistance mechanism of Aspergillus fumigatus. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 1738-44	5.9	20
158	Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases. *Expert Review of Anti-Infective Therapy*, **2015**, 13, 9-27	5.5	34
157	Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 2299-304	5.9	35
156	Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model. *Journal of Antimicrobial Chemotherapy*, **2014**, 69, 1611-9	5.1	23
155	Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. *Lancet Infectious Diseases, The*, **2014**, 14, 498-509	25.5	534
154	Consistent global approach on reporting of colistin doses to promote safe and effective use. *Clinical Infectious Diseases*, **2014**, 58, 139-41	11.6	51
153	Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. *Journal of Antimicrobial Chemotherapy*, **2014**, 69, 715-23	5.1	86
152	EUCAST testing of Isavuconazole susceptibility in Aspergillus: comparison of results for Inoculum standardization using Conidium counting versus optical density. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 6432-6	5.9	12
151	Inhaled antibiotics: dry or wet?. *European Respiratory Journal*, **2014**, 44, 1308-18	13.6	44
150	Black yeasts and their filamentous relatives: principles of pathogenesis and host defense. *Clinical Microbiology Reviews*, **2014**, 27, 527-42	34	69

149	The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside. *Drug Resistance Updates*, **2014**, 17, 37-50	23.2	74
148	Intrapulmonary posaconazole penetration at the infection site in an immunosuppressed murine model of invasive pulmonary aspergillosis receiving oral prophylactic regimens. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 2964-7	5.9	11
147	Isolation of ciprofloxacin-resistant Legionella pneumophila in a patient with severe pneumonia. *Journal of Antimicrobial Chemotherapy*, **2014**, 69, 2869-71	5.1	34
146	Setting Clinical MIC Breakpoints from a PK/PD Point of View: It Is the Dose That Matters **2014**, 45-61		5
145	Continuous Infusion of Beta-lactam Antibiotics **2014**, 223-255		0
144	Treatment of extensively drug-resistant Gram-negative infections in critically ill patients: Outcome of a consensus meeting at the 13th Asia-Pacific Congress of Clinical Microbiology and Infection, October 2012. *Journal of Global Antimicrobial Resistance*, **2013**, 1, 117-122	3.4	5
143	Continuous infusion of amphotericin B deoxycholate for the treatment of life-threatening Candida infections. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 188, 1033	10.2	2
142	Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. *Expert Review of Anti-Infective Therapy*, **2013**, 11, 931-41	5.5	56
141	A structural comparison of lipopolysaccharide biosynthesis loci of Legionella pneumophila serogroup 1 strains. *BMC Microbiology*, **2013**, 13, 198	4.5	12
140	Controlling antimicrobial resistance: Interfering in the process of natural selection. *Antimicrobial Resistance and Infection Control*, **2013**, 2, 32	6.2	2
139	Correlation of MIC value and disk inhibition zone diameters in clinical Legionella pneumophila serogroup 1 isolates. *Diagnostic Microbiology and Infectious Disease*, **2013**, 76, 339-42	2.9	12
138	Global survey of polymyxin use: A call for international guidelines. *Journal of Global Antimicrobial Resistance*, **2013**, 1, 131-134	3.4	33
137	Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance. *International Journal of Antimicrobial Agents*, **2013**, 42, 80-2	14.3	18
136	Inhibitory and fungicidal effects of antifungal drugs against Aspergillus species in the presence of serum. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 1625-31	5.9	18
135	EUCAST expert rules in antimicrobial susceptibility testing. *Clinical Microbiology and Infection*, **2013**, 19, 141-60	9.5	386
134	Azole-resistant Aspergillus fumigatus, Iran. *Emerging Infectious Diseases*, **2013**, 19, 832-4	10.2	50
133	In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 796-803	5.9	32
132	Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 1866-71	5.9	36

131	Monte Carlo simulations based on phase 1 studies predict target attainment of ceftobiprole in nosocomial pneumonia patients: a validation study. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 2047-53	5.9	25
130	Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. *Journal of Antimicrobial Chemotherapy*, **2013**, 68, 900-6	5.1	86
129	Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 4656-63	5.9	23
128	Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis. *Journal of Antimicrobial Chemotherapy*, **2013**, 68, 385-93	5.1	58
127	Combination of pantothenamides with vanin inhibitors as a novel antibiotic strategy against gram-positive bacteria. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 4794-800	5.9	26
126	Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 303-8	5.9	15
125	The therapeutic effect of tigecycline, unlike that of Ceftazidime, is not influenced by whether the Klebsiella pneumoniae strain produces extended-spectrum β-lactamases in experimental pneumonia in rats. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 643-6	5.9	9
124	Composite survival index to compare virulence changes in azole-resistant Aspergillus fumigatus clinical isolates. *PLoS ONE*, **2013**, 8, e72280	3.7	16
123	Consumption of antimicrobials in pigs, veal calves, and broilers in the Netherlands: quantitative results of nationwide collection of data in 2011. *PLoS ONE*, **2013**, 8, e77525	3.7	82
122	The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. *Clinical Microbiology and Infection*, **2012**, 18, E37-45	9.5	180
121	Wild-type MIC distribution and epidemiological cut-off values in clinical Legionella pneumophila serogroup 1 isolates. *Diagnostic Microbiology and Infectious Disease*, **2012**, 72, 103-8	2.9	41
120	A role for TLR1, TLR2 and NOD2 in cytokine induction by Bacteroides fragilis. *Cytokine*, **2012**, 60, 861-9	4	7
119	Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. *Drug Resistance Updates*, **2012**, 15, 149-61	23.2	197
118	The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 186, 559-65	10.2	146
117	Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia. *Clinical Infectious Diseases*, **2012**, 54, 268-74	11.6	71
116	Extensive genetic diversity within the Dutch clinical Cryptococcus neoformans population. *Journal of Clinical Microbiology*, **2012**, 50, 1918-26	9.7	49
115	Resistance of Asian Cryptococcus neoformans serotype A is confined to few microsatellite genotypes. *PLoS ONE*, **2012**, 7, e32868	3.7	38
114	Assessment of efficacy of antifungals in experimental models of invasive aspergillosis in an era of emerging resistance: the value of real-time quantitative PCR. *Current Opinion in Pharmacology*, **2011**, 11, 486-93	5.1	10

113	In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. *Diagnostic Microbiology and Infectious Disease*, **2011**, 71, 370-7	2.9	36
112	Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. *Drug Resistance Updates*, **2011**, 14, 107-17	23.2	141
111	In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs. *Mycoses*, **2011**, 54, e583-9	5.2	43
110	Protein binding: do we ever learn?. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 3067-74	5.9	181
109	Relationship between pharmacodynamic indices and killing patterns in vitro. *Future Microbiology*, **2011**, 6, 613-6	2.9	3
108	Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazole. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 3564-6	5.9	34
107	Clinical impact of preincubation of blood cultures at 37°C. *Journal of Clinical Microbiology*, **2011**, 49, 275-80	3.7	18
106	Chlamydia antibody testing and diagnosing tubal pathology in subfertile women: an individual patient data meta-analysis. *Human Reproduction Update*, **2011**, 17, 301-10	15.8	32
105	Method for phenotypic detection of extended-spectrum beta-lactamases in enterobacter species in the routine clinical setting. *Journal of Clinical Microbiology*, **2011**, 49, 2711-3	9.7	10
104	Pharmacokinetics of clindamycin in pregnant women in the peripartum period. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 2175-81	5.9	31
103	Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?. *Journal of Antimicrobial Chemotherapy*, **2010**, 65, 2141-8	5.1	117
102	Evaluation of Etest to determine tigecycline MICs for Enterobacter species. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 2746-7	5.9	10
101	Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 4758-64	5.9	76
100	Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 860-5	5.9	105
99	Pharmacodynamics of anti-infective agents **2010**, 49-59		
98	Pharmacokinetics of amoxicillin in maternal, umbilical cord, and neonatal sera. *Antimicrobial Agents and Chemotherapy*, **2009**, 53, 1574-80	5.9	14
97	Dose-response relationships of three amphotericin B formulations in a non-neutropenic murine model of invasive aspergillosis. *Medical Mycology*, **2009**, 47, 802-7	3.9	9
96	5-Flucytosine **2009**, 307-315		

95	Concentration-dependency of beta-lactam-induced filament formation in Gram-negative bacteria. *Clinical Microbiology and Infection*, **2008**, 14, 344-9	9.5	25
94	The influence of labour on the pharmacokinetics of intravenously administered amoxicillin in pregnant women. *British Journal of Clinical Pharmacology*, **2008**, 66, 866-74	3.8	20
93	Rapid and reliable identification of Streptococcus anginosus group isolates to the species level by real-time PCR and melting curve analysis. *Journal of Microbiological Methods*, **2008**, 75, 372-4	2.8	7
92	Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. *Journal of Antimicrobial Chemotherapy*, **2008**, 61, 382-8	5.1	61
91	In vitro activities at pH 5.0 and pH 7.0 and in vivo efficacy of flucytosine against Aspergillus fumigatus. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 4483-5	5.9	18
90	Therapeutic drug monitoring of voriconazole. *Therapeutic Drug Monitoring*, **2008**, 30, 403-11	3.2	107
89	Amoxicillin pharmacokinetics in pregnant women with preterm premature rupture of the membranes. *American Journal of Obstetrics and Gynecology*, **2008**, 198, 108.e1-6	6.4	15
88	Tissue concentrations: do we ever learn?. *Journal of Antimicrobial Chemotherapy*, **2008**, 61, 235-7	5.1	274
87	Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 3049-55	5.9	40
86	Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 3599-604	5.9	104
85	Continuous administration of PBP-2- and PBP-3-specific beta-lactams causes higher cytokine responses in murine Pseudomonas aeruginosa and Escherichia coli sepsis. *Journal of Antimicrobial Chemotherapy*, **2007**, 59, 926-33	5.1	21
84	Pharmacokinetics of penicillin G in infants with a gestational age of less than 32 weeks. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 3720-5	5.9	22
83	Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 3605-11	5.9	22
82	Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 3449-51	5.9	51
81	Continuous infusion of beta-lactams. *Current Opinion in Critical Care*, **2007**, 13, 598-606	3.5	81
80	Applying Pharmacodynamics for Susceptibility Breakpoint Selection and Susceptibility Testing. *Infectious Disease and Therapy*, **2007**, 21-44		9
79	The Predictive Value of Laboratory Tests for Efficacy of Antibiotic Combination Therapy. *Infectious Disease and Therapy*, **2007**, 103-128		3
78	Pharmacokinetics and Pharmacodynamics of?Azoles. *Infectious Disease and Therapy*, **2007**, 327-354		3

77	Effect of treatment duration on pharmacokinetic/pharmacodynamic indices correlating with therapeutic efficacy of ceftazidime in experimental Klebsiella pneumoniae lung infection. *Antimicrobial Agents and Chemotherapy*, **2006**, 50, 2919-25	5.9	22
76	European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical Notes on antimicrobial susceptibility testing. *Clinical Microbiology and Infection*, **2006**, 12, 501-3	9.5	114
75	EUCAST Technical Note on daptomycin. *Clinical Microbiology and Infection*, **2006**, 12, 599-601	9.5	25
74	Pathophysiology of in-vitro induced filaments, spheroplasts and rod-shaped bacteria in neutropenic mice. *Clinical Microbiology and Infection*, **2006**, 12, 1105-11	9.5	6
73	EUCAST Technical Note on linezolid. *Clinical Microbiology and Infection*, **2006**, 12, 1243-5	9.5	8
72	EUCAST technical note on tigecycline. *Clinical Microbiology and Infection*, **2006**, 12, 1147-9	9.5	64
71	Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. *Journal of Antimicrobial Chemotherapy*, **2005**, 55, 601-7	5.1	387
70	Rapid and reliable real-time PCR assay for detection of the macrolide efflux gene and subsequent discrimination between its distinct subclasses mef(A) and mef(E). *Journal of Microbiological Methods*, **2005**, 60, 269-73	2.8	7
69	A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit. *Clinical Therapeutics*, **2005**, 27, 762-72	3.5	50
68	Pharmacodynamics of tobramycin in patients with cystic fibrosis. *Diagnostic Microbiology and Infectious Disease*, **2005**, 52, 123-7	2.9	52
67	Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. *Clinical Pharmacokinetics*, **2005**, 44, 201-10	6.2	105
66	Relationship between minimum inhibitory concentration and stationary concentration revisited: growth rates and minimum bactericidal concentrations. *Clinical Pharmacokinetics*, **2005**, 44, 767-8	6.2	17
65	New dosing strategies for antibacterial agents in the neonate. *Seminars in Fetal and Neonatal Medicine*, **2005**, 10, 185-94	3.7	68
64	Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. *Medical Mycology*, **2005**, 43, 133-52	3.9	80
63	In-vitro susceptibility and molecular characterisation of macrolide resistance mechanisms among Streptococcus pneumonia isolates in The Netherlands: the DUEL 2 study. *Clinical Microbiology and Infection*, **2005**, 11, 312-8	9.5	6
62	Impact of Pharmacodynamics on Dosing Schedules: Optimizing Efficacy, Reducing Resistance, and Detection of Emergence of Resistance **2005**, 387-407		1
61	Use of a novel panel of nine short tandem repeats for exact and high-resolution fingerprinting of Aspergillus fumigatus isolates. *Journal of Clinical Microbiology*, **2005**, 43, 4112-20	9.7	192
60	Duration of antibiotic treatment: are even numbers odd?. *Journal of Antimicrobial Chemotherapy*, **2005**, 56, 441-2	5.1	5

59	Molecular detection of the macrolide efflux gene: to discriminate or not to discriminate between mef(A) and mef(E). *Antimicrobial Agents and Chemotherapy*, **2005**, 49, 1271-8	5.9	48
58	Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole. *Antimicrobial Agents and Chemotherapy*, **2004**, 48, 1335-43	5.9	52
57	Which cephalosporin for gonorrhoea?. *Sexually Transmitted Infections*, **2004**, 80, 386-8	2.8	19
56	Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. *Antimicrobial Agents and Chemotherapy*, **2004**, 48, 1713-8	5.9	68
55	Amplified fragment length polymorphism fingerprinting is an effective technique to distinguish streptococcus pneumoniae from other Streptococci and an efficient alternative to pulsed-field gel electrophoresis for molecular typing of pneumococci. *Journal of Clinical Microbiology*, **2004**, 42, 369-71	9.7	8
54	Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo in mixed-infection abscesses.	5.9	19
53	Pneumolysin is a key factor in misidentification of macrolide-resistant Streptococcus pneumoniae and is a putative virulence factor of S. mitis and other streptococci. *Journal of Clinical Microbiology*, **2004**, 42, 4355-7	9.7	35
52	Vancomycin: pharmacokinetics and administration regimens in neonates. *Clinical Pharmacokinetics*, **2004**, 43, 417-40	6.2	102
51	In vitro susceptibilities of zygomycetes to conventional and new antifungals. *Journal of Antimicrobial Chemotherapy*, **2003**, 51, 45-52	5.1	246
50	Thoughts on "Population pharmacokinetics and relationship between demographic and clinical variables and pharmacokinetics of gentamicin in neonates". *Therapeutic Drug Monitoring*, **2003**, 25, 256-7; author reply 257	3.2	4
49	Impact of pharmacodynamics on breakpoint selection for susceptibility testing. *Infectious Disease Clinics of North America*, **2003**, 17, 579-98	6.5	41
48	European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. *Journal of Antimicrobial Chemotherapy*, **2003**, 52, 145-8	5.1	266
47	In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. *Antimicrobial Agents and Chemotherapy*, **2003**, 47, 106-17	5.9	204
46	Evaluation of the post-antifungal effect (PAFE) of amphotericin B and nystatin against 30 zygomycetes using two different media. *Journal of Antimicrobial Chemotherapy*, **2003**, 52, 65-70	5.1	13
45	Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis. *Antimicrobial Agents and Chemotherapy*, **2003**, 47, 541-7	5.9	48
44	Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring. *Clinical Pharmacology and Therapeutics*, **2002**, 71, 349-58	6.1	31
43	Effect of a single percutaneous abscess drainage puncture and imipenem therapy, alone or in combination, in treatment of mixed-infection abscesses in mice. *Antimicrobial Agents and Chemotherapy*, **2002**, 46, 3712-8	5.9	12
42	Comparison of the Etest and the sensititre colorimetric methods with the NCCLS proposed standard for antifungal susceptibility testing of Aspergillus species. *Journal of Clinical Microbiology*, **2002**, 40, 2876-85	9.7	49

41	Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection. *Antimicrobial Agents and Chemotherapy*, **2002**, 46, 2575-81	5.9	38
40	In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. *Antimicrobial Agents and Chemotherapy*, **2002**, 46, 62-8	5.9	205
39	Why the AUC/MIC ratio should not be used to predict the effects of beta-lactams. *Clinical Infectious Diseases*, **2002**, 35, 209-10	11.6	2
38	Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis. *Antimicrobial Agents and Chemotherapy*, **2002**, 46, 1953-9	5.9	47
37	In vitro susceptibilities of Zygomycota to polyenes. *Journal of Antimicrobial Chemotherapy*, **2002**, 49, 741-4	5.1	16
36	Method for measuring postantifungal effect in Aspergillus species. *Antimicrobial Agents and Chemotherapy*, **2002**, 46, 1960-5	5.9	22
35	In vitro activities of pentamidine, pyrimethamine, trimethoprim, and sulfonamides against Aspergillus species. *Antimicrobial Agents and Chemotherapy*, **2002**, 46, 2029-31	5.9	21
34	Methodological issues related to antifungal drug interaction modelling for filamentous fungi. *Reviews in Medical Microbiology*, **2002**, 13, 101-117	1.1	11
33	Breakpoints: current practice and future perspectives. *International Journal of Antimicrobial Agents*, **2002**, 19, 323-31	14.3	55
32	Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. *International Journal of Antimicrobial Agents*, **2002**, 19, 355-8	14.3	83
31	The epidemiology of vaginal colonisation with group B streptococci in a sexually transmitted disease clinic. *European Journal of Obstetrics, Gynecology and Reproductive Biology*, **2002**, 105, 177-80	2.4	18
30	The DUEL study: a multi-center in vitro evaluation of linezolid compared with other antibiotics in the Netherlands. *Clinical Microbiology and Infection*, **2001**, 7, 486-91	9.5	14
29	Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis [2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide], for antifungal susceptibility testing of Aspergillus species. *Journal of Clinical Microbiology*, **2001**, 39, 4256-63	9.7	67
28	In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model. *Antimicrobial Agents and Chemotherapy*, **2001**, 45, 1394-401	5.9	16
27	Colorimetric assay for antifungal susceptibility testing of Aspergillus species. *Journal of Clinical Microbiology*, **2001**, 39, 3402-8	9.7	142
26	Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats. *Antimicrobial Agents and Chemotherapy*, **2001**, 45, 1487-92	5.9	34
25	Prevention of invasive aspergillosis in AIDS by sulfamethoxazole. *Aids*, **2001**, 15, 1067-8	3.5	7
24	Combination chemotherapy for the treatment of invasive infections by Scedosporium prolificans. *Clinical Microbiology and Infection*, **2000**, 6, 336-7	9.5	33

23	Aerosol therapy in cystic fibrosis: a survey of 54 CF centers. *Pediatric Pulmonology*, **2000**, 30, 368-76	3.5	19
22	Vancomycin population pharmacokinetics in neonates. *Clinical Pharmacology and Therapeutics*, **2000**, 67, 360-7	6.1	55
21	In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. *Antimicrobial Agents and Chemotherapy*, **2000**, 44, 470-2	5.9	88
20	Antibiotic treatment in cystic fibrosis. *Antimicrobics and Infectious Diseases Newsletter*, **2000**, 18, 25-29		1
19	Antibiotic treatment in cystic fibrosis. *Antimicrobics and Infectious Diseases Newsletter*, **2000**, 18, 33-37		
18	Comparative pharmacokinetics of the carbapenems: clinical implications. *Clinical Pharmacokinetics*, **2000**, 39, 185-201	6.2	140
17	Comparison of NCCLS and 3-(4,5-dimethyl-2-Thiazyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. *Journal of Clinical Microbiology*, **2000**, 38, 2949-54	9.7	175
16	Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. *Antimicrobial Agents and Chemotherapy*, **1999**, 43, 2473-8	5.9	61
15	Lung clearance of intratracheally instilled 99mTc-tobramycin using pulmonary surfactant as vehicle. *British Journal of Pharmacology*, **1999**, 126, 1091-6	8.6	19
14	Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions. *Clinical Pharmacokinetics*, **1998**, 35, 437-59	6.2	55
13	Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics. *Antimicrobial Agents and Chemotherapy*, **1998**, 42, 744-8	5.9	50
12	Duration and clinical relevance of postantibiotic effect in relation to the dosing interval. *Antimicrobial Agents and Chemotherapy*, **1998**, 42, 749-54	5.9	30
11	Comparison of pharmacodynamics of azithromycin and erythromycin in vitro and in vivo. *Antimicrobial Agents and Chemotherapy*, **1998**, 42, 377-82	5.9	43
10	Tobramycin population pharmacokinetics in neonates. *Clinical Pharmacology and Therapeutics*, **1997**, 62, 392-9	6.1	42
9	Reduction of Surgical-Site Infections in Cardiothoracic Surgery by Elimination of Nasal Carriage of Staphylococcus aureus. *Infection Control and Hospital Epidemiology*, **1996**, 17, 780-785	2	188
8	Exogenous pulmonary surfactant as a drug delivering agent: influence of antibiotics on surfactant activity. *British Journal of Pharmacology*, **1996**, 118, 593-8	8.6	25
7	Pulmonary surfactant as vehicle for intratracheally instilled tobramycin in mice infected with Klebsiella pneumoniae. *British Journal of Pharmacology*, **1996**, 119, 1145-8	8.6	44
6	Typing of Pseudomonas aeruginosa strains from patients with cystic fibrosis: phenotyping versus genotyping. *Clinical Microbiology and Infection*, **1996**, 1, 261-265	9.5	16

5	Meropenem clinical pharmacokinetics. *Clinical Pharmacokinetics*, **1995**, 28, 275-86	6.2	70
4	Emergence of antibiotic resistance amongst Pseudomonas aeruginosa isolates from patients with cystic fibrosis. *Journal of Antimicrobial Chemotherapy*, **1993**, 31, 919-26	5.1	61
3	Oral immunization with polyvalent bacterial lysate and infection with Streptococcus pneumoniae: influence on interferon-gamma and PMN elastase concentrations in murine bronchoalveolar lavage fluid. *International Archives of Allergy and Immunology*, **1992**, 97, 173-7	3.7	5
2	Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion. *Journal of Antimicrobial Chemotherapy*, **1991**, 28, 911-8	5.1	39
1	Antibacterial therapy in cystic fibrosis. *Medical Clinics of North America*, **1990**, 74, 837-50	7	16